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OBJECTIVES: In common with other chronic conditions, fibromyalgia syndrome
(FMS) adversely affects Health-Related Quality of Life (HRQoL) and functional sta-
tus. FMS often results in disability and profoundly affects the performance of daily
activities, both at work and at home. This study was conducted to assess the
patient-level burden among subjects with FMS. METHODS: A prospective, obser-
vational studywas carried out on FMSpatients from44medical centers throughout
Korea. HRQoL scores were obtained using the Short Form (SF)-36 Health Survey. To
estimate recent 3month healthcare and non-healthcare cost, and productivity loss
of FMS patients, participants completed a standardized questionnaire. Cost items
mainly included healthcare cost such as outpatient, pharmacy, inpatient, and ori-
ental medicine; non-healthcare cost such as traffic expenses, nursing cost, com-
plementary and alternative medicine. Cost included insurance-covered cost as
well as patient’s out-of-pocket expenses during 3months. To estimate productivity
loss due to morbidity, days away from work due to FMS were also investigated.
RESULTS: Among 1,040 FMS patients who completed the questionnaire, female
was 92% (n957). Approximately 45.7% of patients had rheumatic diseases. HRQoL
physical component mean scores were determined as 35.97.5, and mental com-
ponent mean scores were determined as 34.612.6. Number of out-patient visits
within 3 months was 4.06.5. Total costs over 3 months were 1,6092,055 USD.
Within 3 months, 23.4% and 91.2% of patients with FMS had been away from work
and reported the decreased work productivity, respectively. In the preceding 3
months, FMS patientsmissed 20 (SD28.1) days of work, left work early an average
of 28 (SD31.0) days, and accomplished less at work an average of 65 (SD30.0)
days. CONCLUSIONS: Our results suggested that the patient-level burden among
FMS sufferers in Korea is significant, evidenced by negative effect on health-related
quality of life, health resource use and work/activity limitations.
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OBJECTIVES: Golimumab was recently approved by the Food and Drug Adminis-
tration onApril 24, 2009 for use in patients with rheumatoid arthritis (RA), psoriatic
arthritis (PsA), or ankylosing spondylitis (AS). The objective of this study was to
compare baseline demographic and clinical characteristics and pre-index total/RA-
related healthcare costs in patients receiving golimumab with/without biologic
experience. METHODS: The IMS LifeLink™ Health Plan database was utilized to
identify patients with an: age 18 years at index; index golimumab pharmacy
claim started 4/24/2009-10/31/2009;1 RA, PsA, or AS ICD-9 diagnosis code; and 24
months pre- and 2 months post-index continuous enrollment. RESULTS: A total
of 282 patients (n206 with pre-index biologic experience) receiving golimumab
were identified; mean SD age was 52 12; 72% female. No significant differences
in demographic characteristics existed between patients with/without biologic ex-
perience. The top three rheumatologic conditions were RA (79%), PsA (26%), and AS
(10%). Hypertension (45%), dyslipidemia (40%), and diabetes (17%) were the most
prevalent comorbidities prior to starting golimumab. Pre-index total healthcare
costs (mean, median) were significantly higher for biologic experienced patients
($59,979, $46,075) compared to non-biologic experienced patients ($21,002, $12,662;
p0.001). Among the 178 patients with an RA diagnosis only, pre-index total RA-
related costs (mean, median) were significantly higher for patients with biologic
experience ($29,701, $27,464) than those without ($6,045, $1,937; p0.001). Overall
mean  SD RA-related medication costs ($17,193  $16,619) were greater than
RA-related outpatient or inpatient costs ($5,239  $14,912 and $225  $3,001,
respectively). CONCLUSIONS:When examining baseline clinical characteristics of
patients receiving golimumab, results showed that the majority of patients were
diagnosed with RA, and had concomitant hypertension, dyslipidemia, or diabetes.
Most patients received another biologic prior to golimumab. Biologic experienced
patients were more costly at baseline. These characteristics should be adjusted for
in comparative analyses including golimumab.
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OBJECTIVES: To determine payments made by commercial healthcare providers
for adults diagnosed with obesity, and those comorbid with any combination of
certain chronic conditions: diabetes mellitus (DM), hypertension, depression,
and/or congestive heart failure (CHF).METHODS:We utilized a 10% random sam-
pling from MarketScan, a commercial claims and encounters database
(n12,416,190). The study population (n50,717) was limited to thosewho: (1) were
adults age 18-64; (2) filed claims between 2006-2007; (3) had at least one inpatient
visit, one outpatient visit, or one emergency department visit; and, (4) were given a
primary or secondary diagnosis of obesity. Persons were identified and categorized
if they had one ormore comorbid diagnoses (DM, hypertension, depression, and/or
CHF) in addition to obesity. After adjusting for age and gender, we calculated the
mean total net expenditures (in $US 2007) for each combination of comorbid con-
ditions. All calculations were performed in Stata. RESULTS: Among those diag-
nosedwith obesity, themean net expenditures for services were $1799 per patient.
Persons diagnosed with obesity and other comorbidities observed an increase in
total net expenditures. Obesity and hypertension observed the highest increase
among single comorbidities at $4298. For persons with obesity and two other co-
morbidities, DM and depression was the highest at $14364. The most expensive
condition in the study sample was obesity, DM, hypertension and depression at
$14843. All results were statistically significant at the 95% confidence level.
CONCLUSIONS: Compared to the average medical claim, persons diagnosed with
obesity along with other common chronic conditions experience significant in-
creases in healthcare costs. These costs are often drivenhigher by the time spent as
inpatients. In many cases, obesity may be the cause of other chronic conditions
that result in these high costs. Thus, by controlling and reducing the prevalence of
obesity, we may see significant decreases in healthcare expenditures.
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OBJECTIVES: Patients managing chronic non-cancer pain with cytochrome P450
(CYP450)-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxy-
codone, tramadol) analgesics who concurrently take another CYP450-metabolized
medication experience a drug-drug exposure (DDE), which puts them at risk for a
pharmacokinetic drug-drug interaction (DDI). This study examined whether patients
with an incident DDE with the potential to cause a DDI had greater healthcare costs
compared to similar patients without such exposure. METHODS: Propensity score
matchingwas used to control for baseline differences in an insured population chron-
ically using these opioid analgesics during the period, January 1, 2004 throughDecem-
ber 31, 2008. Estimates of the predicted likelihood of a DDE occurrence for thematch-
ing model were derived from patient age, gender, geographical location, number of
unique concurrentmedications, co-morbidities, services utilization, and total costs in
the six-months pior to the index date. Comparisonsweremade between 122,586 DDE
and 122,586 no-DDE patients. RESULTS: Comparisons yielded mean total costs six
months after an incident DDE that were significantly higher for younger ( 65 years
old) patients with DDE versus matched no-DDE patients ($8,165 vs. $7,498, respec-
tively, resulting in a difference of $667, p0.01). Similarly among older ( 65years old)
patients, mean total costs at six months were significantly higher for patients with
DDE compared to matched no-DDE patients ($9,598 vs. $9,030, respectively, resulting
in a difference of $568, p0.01). The direction, magnitude and significance of these
differences persisted after sensitivity analyses. CONCLUSIONS: Although it is impos-
sible to establish causal relationships in claims database studies, this study demon-
strates a strong association of the economic consequences of DDEs that are avoidable.
Sinceconcurrentexposure tomultipledrugsmetabolized through theCYP450enzyme
system may be relatively common, policy decisions should include consideration of
the use of long-acting opioids that are not metabolized through the CYP450 pathway.
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OBJECTIVES: Although hemophilia may have a large economic impact on patients
and healthcare systems, published estimates of costs for care of U.S. hemophilia
patients are sparse. The objective of this study is to estimate average annual costs
of health care for hemophilia patients in the United States, stratified according to
the influence of age, type of hemophilia [A (factor VIII deficiency) versus B (factor
IX)], presence of neutralizing alloantibody inhibitors, and exposure to blood-borne
viral infections.METHODS: Data from the MarketScan® Commercial and Medicare
Research Databases were used for the period 2002-2008 to identify cases of hemo-
philia and to estimatemedical expenditures during 2008. RESULTS: A total of 1,164
male hemophilia patients were identified, 933 with hemophilia A and 231 with
hemophilia B. Their average annual costs for health care in 2008 were $155,136.
Average annual costs for 30 (3%) hemophilia A patients with an inhibitor were 5
times higher than for other hemophilia patients, approximately $697,000 and
$144,000, respectively. Clotting factor concentrate accounted for 70%–82% of total
costs. Average costs for 207 adult patients with HCV or HIV infectionwere 1.5 times
higher than those for adults without infection. A subset of adults with viral infec-
tion had particularly high use of factor concentrate and costs. CONCLUSIONS:
Hemophilia treatment is associated with a significant economic burden, particu-
larly for patients with neutralizing alloantibody inhibitors who require bypassing
agents for treatment. The excess costs of care associated with blood-borne viral
infection are concentrated among a subset of hemophilia patients.
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OBJECTIVES:Obesity, defined as bodymass index (BMI) 30, is amajor contributor
to increased morbidity, mortality, and healthcare expenditures. There is a ten-
dency for obese individuals to continually gain weight over their lifetimes. How-
ever, neither the strength of this tendency nor its economic consequences are well
understood. We constructed a health outcomes model from a societal perspective
to assess this.METHODS: Our model projected lifetime trajectories for BMI, death,
cost, and quality-adjusted life years (QALYs). Using these projections, we com-
puted the net economic value of potential weight loss for an individual given base-
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